Q4 2019 Earnings Call

These statements are based upon the information available to the company today and out there assumes no obligation to update these statements as circumstances change future events and actual results could differ materially from those projected in the company's forward-looking statement additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in great detail, and the company's press release issued this morning containing Financial results for the year ended December Thirty One 2019, and the company's filings with the SEC now. I will take the call over to dr. Brady. Thank you Joshua and good morning everyone. Thank you for joining us.

today I want to touch on the

Progress we've made regarding our strategy to develop and commercialize novel medicines for patients whose conditions are not adequately being treated by current Therapies in a particular. I want to discuss the announcement. We made this morning to focus that strategy on our late-stage Pipeline and ocular disease that decision that extends our cash wrong way through the end of 2021 during our recent R&D day in New York. We highlighted the statistically significant and clinically relevant data off observed in late-stage clinical trials of our lead asset an allergic conjunctivitis and dry eye disease these conditions currently make up the majority of anterior or inflammatory disease which affects more than 40% of the US population and more than 1 billion people worldwide the economic wage.

Allergy and dry a disease is expected to accelerate exacerbated by pollution global warming Rising pollen counts and increasing urbanization. These Trends play directly into our drug development initiatives for approximately as we noted during the R&D dated a trip has demonstrated significant and clinically relevant effects.